Navigation Links
Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
Date:5/14/2008

SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its average monthly cash expenditures going forward are unlikely to exceed $1 million, made up of the following categories:

* Costs related to the Company's real estate and facility, estimated at

32% of monthly expenditures.

* Costs related to maintaining public company status, including

professional fees, at approximately 32% of monthly expenditures.

* Costs related to the company's six remaining permanent staff and

temporary support, at approximately 21% of monthly expenditures.

* Interest payments associated with the outstanding convertible debt at

approximately 15% of monthly expenditures.

"With the completion of the most recent reduction in force, we have concluded those significant cost-reduction measures that are under the Company's sole control," said James P. Panek, VaxGen President and CEO. "While we continue to explore every avenue to reduce costs, a further significant reduction will be a function of the resolution of our efforts to sell the manufacturing plant and assign the associated lease. We are in discussions with parties interested in the plant, but cannot at this point provide assurance that a transaction will result."

VaxGen further announced today the filing of its financial results for the quarter ending March 31, 2008 on Form 10-Q with the Securities and Exchange Commission. These results reflect a number of significant impacts consequent to the termination of the proposed merger with Raven biotechnologies as follows:

* Consistent with SFAS 144, "Accounting for the Impairment and Disposal of

Long-Lived Assets" the property and equipment related to VaxGen's
'/>"/>

SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
2. VaxGen and Raven Terminate Merger Agreement
3. VaxGen Issues Rebuttal to MedCap Letter
4. VaxGen Common Stock Now Quoted on OTC Bulletin Board
5. VaxGen Reports Financial Update
6. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
7. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
10. VaxGen Addresses MPM Claims in Letter to Stockholders
11. VaxGen Files Last Outstanding Periodic Report With SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy.  ... ASCO annual meeting is the pre-eminent conference focused on ...
(Date:5/23/2013)... 23, 2013  Verenium Corporation (Nasdaq: VRNM ... development and commercialization of high-performance enzymes, today announced that ... will present at two upcoming conferences. (Logo: ... at the Second Annual Marcum LLP Microcap Conference on ... in New York City.  The presentation is scheduled to ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx ... treatment of sleep related breathing disorders (SRBDs), announced today ... CEO & President and his election to the Board ... Letendre will be responsible for spearheading the clinical, regulatory, ...
... Nanotecnologia (ICN), in Barcelona, has demonstrated a device that induces ... in developing the spin computers of the future. The results ... Science. The authors are Marius V. Costache and Sergio O. ... and Engineering of Nanodevices Group at ICN. Spintronics is ...
... 2010 The new biotechnology curriculum at Bunker Hill ... state to win a Silver endorsement from the new ... the College,s program acknowledges that it is successfully training ... state to keep a competitive edge. To ...
Cached Biology Technology:Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director 2A 'spin ratchet': A new electronic structure for generating spin current 2Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses 2
(Date:5/24/2013)... In the search for medication against Alzheimer,s disease, scientists have ... break down Amyloid beta (A-beta). After all, it is the ... brains of Alzheimer,s patients. Starting point for the formation of ... were the first to unravel the function of APPL ... healthy fruit flies. , Alessia Soldano (VIB/KU Leuven): "We ...
(Date:5/23/2013)... Northwest National Laboratory honored more than 165 staff ... property at PNNL,s annual Intellectual Property Commercialization Recognition ... of Energy national laboratory named materials scientist Jun ... developing battery materials that can store large amounts ... and reduce the time it takes to charge ...
(Date:5/23/2013)... of genomic DNA around nucleosomes in the cell ... team of Ludwig-Maximilians-Universitaet (LMU) in Munich now describes ... locally displaced from nucleosomes for transcription. , In ... the cell nucleus, wrapped around disk-shaped particles called ... different histone proteins and accommodating two loops of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2
... A new study has found that protein and not ... and burning calories. The research, published in the ... , has implications for understanding obesity and sleep disorders. ... which secrete a stimulant called orexin/hypocretin in the brain. ...
... that fuel is present in all vegetative matter that ... day grow their own fuel. Last year, global biofuel ... for 2.7% of the world,s transportation fuel. Bioethanol, a ... food crops such as corn and sugarcane. However, technologies ...
... extinction is a complicated task, especially for species that migrate ... Georgia and Tulane University have developed a mathematical model that ... the early online edition of the Royal Society journal ... lot of species, we don,t know very much about their ...
Cached Biology News:3 p.m. slump? Why a sugar rush may not be the answer 2Toward more cost-effective production of biofuels from plant lignocellulosic biomass 2New model more accurately describes migratory animals' extinction risk 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... raised against a partial recombinant ... TOPORS (NP_005793, 98 a.a. ... protein with GST tag. ... NM_005802 Protein ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
... antibody raised against a partial recombinant NFKBIB. ... ~ 145 a.a) partial recombinant protein with GST ... Accession: BC015528 ... OMIM: 604495, GeneID: ...
Biology Products: